Therapeutic uses of inhibitors of RTP801L

Details Therapeutic uses of inhibitors of RTP801L Therapeutic uses of inhibitors of RTP801L

2007-06-08

2009-12-01

Bowman, Amy (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S024310, C536S024330, C514S04400A

Reexamination Certificate

active

07626015

ABSTRACT:
The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.

REFERENCES:
patent: 5898031 (1999-04-01), Crooke
patent: 6107094 (2000-08-01), Crooke
patent: 6372249 (2002-04-01), Smith et al.
patent: 6455674 (2002-09-01), Einat et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6555667 (2003-04-01), Einat et al.
patent: 6673549 (2004-01-01), Furness et al.
patent: 6740738 (2004-05-01), Einat et al.
patent: 2002/0119463 (2002-08-01), Faris
patent: 2002/0137077 (2002-09-01), Hopkins et al.
patent: 2003/0104973 (2003-06-01), Einat et al.
patent: 2003/0108871 (2003-06-01), Kaser
patent: 2003/0165864 (2003-09-01), Lasek et al.
patent: 2004/0180351 (2004-09-01), Giese et al.
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2006/0217329 (2006-09-01), Feinstein
patent: 2007/0185017 (2007-08-01), Aggarwal et al.
patent: 2007/0185047 (2007-08-01), Bhat
patent: 2007/0224201 (2007-09-01), Wu et al.
patent: 2007/0281326 (2007-12-01), Wechsler et al.
patent: 2008/0014599 (2008-01-01), Wechsler et al.
patent: 2008/0064650 (2008-03-01), Feinstein et al.
patent: 19816395 (1999-10-01), None
patent: 2003-259877 (2003-09-01), None
patent: WO 00/14283 (2000-03-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/61620 (2000-10-01), None
patent: WO 00/77022 (2000-12-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/70979 (2001-09-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 01/77289 (2001-10-01), None
patent: WO 01/12659 (2001-12-01), None
patent: WO 01/96391 (2001-12-01), None
patent: WO 02/31111 (2002-04-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/46465 (2002-06-01), None
patent: WO 02/055693 (2002-07-01), None
patent: WO 02/101075 (2002-12-01), None
patent: WO 03/010205 (2003-02-01), None
patent: WO 03/025138 (2003-03-01), None
patent: WO 03/070918 (2003-08-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO 03/101283 (2003-12-01), None
patent: WO 04/015107 (2004-02-01), None
patent: WO 2004/018999 (2004-03-01), None
patent: WO 2004/031237 (2004-04-01), None
patent: WO 2004/045545 (2004-06-01), None
patent: WO 2004/060270 (2004-07-01), None
patent: WO 2004/076633 (2004-09-01), None
patent: WO 2004/091383 (2004-10-01), None
patent: WO 2005/016000 (2005-02-01), None
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nat. Biotechnol., 21(12), pp. 1457-1465.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Jan. 2005, Expert Opinion on Drug Delivery, vol. 2, No. 1, pp. 3-28.
Zhang et al., Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology, 2004, Current Pharmaceutical Biotechnology, vol. 5, p. 1-7.
Shoshani et al., Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801, Involved in Apoptosis, 2002, Molecular and Cellular Biology, vol. 22, No. 7, pp. 2283-2293.
Holen et al., Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor, 2002, Nucleic Acids Research, vol. 30, No. 8, pp. 1757-1766.
Dudek et al., TROD: T7 RNAi Oligo Designer, 2004, Nucleic Acids Research, vol. 32, W121-W123.
U.S. Appl. No. 11/655,636, filed Jan. 18, 2007, Feinstein and Skaliter.
U.S. Appl. No. 12/072,392, filed Feb. 26, 2008, Feinstein and Skaliter.
Elena Feinstein and Rami Skaliter, U.S. Appl. No. 11/655,636, filed Jan. 18, 2007 pending claims.
Elena Feinstein and Rami Skaliter, U.S. Appl. No. 12/072,392, filed Feb. 26, 2008 and pending claims.
Amarzguioui M, Holen T, Babaie E, Prydz H. (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31(2):589-95.
Barik, Sailen (2005). “Silence of the Transcripts; RNA Interference In Medicine,” J. Mol. Med. 83:764-773.
Bartel, David P. et al. (2004). “MircroRNAs: Genomics Biogenesis, Mechanism, and Function,” Cell, 116:281-297.
Bernstein, Emily et al. (2001). “Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference,” Nature, 409:363-366.
Bitko, Vira et al. (2004). “Inhibition of Respiratory Viruses By Nasally Administered siRNA,” Nature Medicine, 11(1):50-55.
Brafman, A. et al., (2004) “Inhibition Of Oxygen-Induced Retinopathy In RTP801-Deficient Mice,”Investigative Opthalmology&Visual Science, 45(10): 3796-3805.
Brugarolas, J. et al., (2004) “Regulation Of mTOR Function In Response To Hypoxia By REDD1 And The TSC1/TSC2 Tumor Suppressor Complex,”Genes&Development, 18: 2893-2904.
Brummelkamp, Thijn R. et al. (2002).“A System For Stable Expression of Short Interfering RNAs in Mammalian Cells,” Science, 296-550-553.
Caplen, Natasha J. et al. (2001). “Specific Inhibition of Gene Expression By Small Double-Stranded RNAs in Invertebrate Vertebrate Systems,” PNAS, 98(17):9742-9747.
Chakraborty, Chiranjib (2007) “Potentially of Small Interfering RNAs (siRNA) as Recent Therapeutic Targets for Gene-Silencing,” Current Drug Targets, 8:469-482.
Chalk, Alistair M. et al., (2004). “Improved and Autonated Prediction of Effective siRNA,” Biochemical and Biophysical Research Communications, 319:264-274.
Corradetti MN, (2005) The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem. Mar. 18;280 (11) : 9769-72.
Cuaz-perolin et al., (2004) REDD2 gene is upregulated by modified LDL or hypoxia and mediates human macrophage cell death. Arterioscler Thromb Vasc Biol. Oct.; 24 (10) : 1830-5. Epub Aug. 12, 2004.
Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk GJ, Giese K, Kaufmann J. (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003 31 (11) :2705-16.
Elbashir, Sayda M. et al. (2000). “RNA Interference is Mediated By 21- and 22-nucleotide RNAs,” Genes & Development, 15:188-200.
Elbashir, Sayda M. et al. (2001). “Duplexes of 21-nucleotide RNAs mediated RNA interference in cultured mammalian cells,” Nature, 411:494-498.
Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. (2001) Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melanogasterembryo lysate. EMBO J. 20 (23) : 6877-88.
Ellisen LW. (2005) Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle. Nov;4 (11):1500-02.
Ellisen, L. et al., (2002) “REDD1, A Developmentally Regulated Transcriptional Target Of p63 and p53, Links p63 To Regulation Of Reactive Oxygen Species,”Molecular Cell, 10: 995-1005.
Fire, Andrew et al., (1998). “Potent and Specific Genetic Interference By Double-stranded RNA inCaenorhabditis elegans,” Nature, 391:806-811.
Frolov, A. et al., (2003) “Response Markers and The Molecular Mechanisms Of Action Of Gleevec In Gastrointestinal Stromal Tumors,”Molecular Cancer Therapeutics, 2: 699-709.
Honore S, et al. (2005): Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci. Dec;62 (24) : 3039-56.
Jozwiak J, et al. (2005): Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med. 7 (4): 287-96.
Kim, J. et al., (2003) “Identification Of Amyloid β-peptide Responsive Genes By cDNA Microarray Technology: Involvement OfRTP801In Amyloid β-peptide Toxicity,”Experimental and Molecular Medicine, 35 (5): 403-411.
Lal, A. et al., (2001) “Transcriptional Response To Hypoxia In Human Tumors,”Journal of the National Cancer Institute, 93(17): 1337-1343.
Lee, M. et al., (2004) “Sp1-Dependant Regulation Of The RTP801 Promoter And Its Application To Hypoxia-Inducible VEGF Plasmid For Ischemic Disease,”Pharmaceutical Research, 21 (5) : 736-741.
Lee, Youngtae et al., (2003). “T

Affiliated with

Also associated with

Rating

Therapeutic uses of inhibitors of RTP801L does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic uses of inhibitors of RTP801L, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of inhibitors of RTP801L will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4132972